Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02299336 · ClinicalTrials.gov registry record · Phase 4
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
A Phase 4 study, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT02299336 is a Phase 4 study that has completed, run by Greater Houston Retina Research. The registered enrollment target is 60 participants.
The verdict
NCT02299336, a Phase 4 study, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009; NCT01363440) end-point. Subjects will be treated with intravitreal aflibercept injections pro re nata (PRN) based on the presence of CR-DME (Clinically Relevant-DME). In addition, subjects who meet re-treatment criteria will be eligible for focal laser treatment every 90 days.
Interventions
- DRUG Aflibercept
- PROCEDURE Focal Laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-11-24 |
| Est. Completion | 2017-01-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02299336
The ClinicalTrials.gov registry entry for NCT02299336 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Greater Houston Retina Research, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT02299336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02299336 about?
NCT02299336 is a clinical study titled "Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial". The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009; NCT01363440) end-point. Subjects will be treated with intravitreal aflibercept injections pro re nata (PRN) based on the presence o...
What is the current status of trial NCT02299336?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2014-11-24. Estimated completion is 2017-01-09.
What interventions are being tested in trial NCT02299336?
The interventions under investigation include: Aflibercept (DRUG), Focal Laser (PROCEDURE).
Who is sponsoring clinical trial NCT02299336?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.